Thymic carcinoma natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
Marjan Khan (talk | contribs) |
|||
| (14 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Thymic carcinoma}} | {{Thymic carcinoma}} | ||
{{CMG}}; {{AE}} {{ | {{CMG}}; {{AE}} {{Marjan}} | ||
==Overview== | ==Overview== | ||
Thymic carcinomas are generally considered indolent tumors due to long recurrence intervals (median of 68 months). | Thymic carcinomas are generally considered indolent tumors due to long recurrence intervals (median of 68 months). The most common sites of distant recurrence are [[lung]], [[liver]], [[bone]], [[kidney]], [[brain]], and [[bone marrow]].<ref name="www.ncbi.nlm.nih.gov">{{Cite web | last = | first = |title = Recurrence of thymoma: clinicopathological feat... [J Surg Oncol. 2001] - PubMed - NCBI | url = http://www.ncbi.nlm.nih.gov/pubmed/11745803 | publisher = | date = | accessdate = }}</ref> The most important factor for prognosis is the stage and grade of the thymic carcinoma. The 5-year and 10-year overall survival rates in patients with thymic carcinoma are 38% and 28%, respectively.<ref name="Ogawa-2002">{{Cite journal | last1 = Ogawa | first1 = K. | last2 = Toita | first2 = T. | last3 = Uno | first3 = T. | last4 = Fuwa | first4 = N. | last5 = Kakinohana | first5 = Y. | last6 = Kamata | first6 = M. | last7 = Koja | first7 = K. | last8 = Kinjo | first8 = T. | last9 = Adachi | first9 = G. | title = Treatment and prognosis of thymic carcinoma: a retrospective analysis of 40 cases. | journal = Cancer | volume = 94 | issue = 12 | pages = 3115-9 | month = Jun | year = 2002 | doi = 10.1002/cncr.10588 | PMID = 12115342 }}</ref> The subtypes squamous cell carcinoma, mucoepidermoid carcinoma, and basaloid carcinoma have a better prognosis than other histological subtypes. There are no reported cases of complications regarding the carcinoma by itself. Most complications occur during surgery and biopsy. The most important factor for prognosis is the stage and grade of the thymic carcinoma. The 5-year and 10-year overall survival rates in patients with thymic carcinoma are 38% and 28% respectively. Thymic malignancies are among the most common mediastinal primary tumors with up to 50% of anterior mediastinal masses proving to be of thymic descent. Invasive thymomas and thymic carcinomas are relatively rare tumors, which together represent about 0.2% to 1.5% of all malignancies. | ||
==Natural History== | ==Natural History== | ||
*Thymic carcinomas are generally considered indolent tumors due to long recurrence intervals (median of 68 months). | *Thymic carcinomas are generally considered indolent tumors due to long recurrence intervals (median of 68 months). | ||
*Overall, for patients diagnosed with a resectable thymic tumor, 16% of them will recur after radical resection, either | *Overall, for patients diagnosed with a resectable thymic tumor, 16% of them will recur after radical resection, either through local [[pleural]] or ganglionar recurrence or through distant metastatic spread. | ||
*The most common sites of distant recurrence are [[lung]], [[liver]], [[bone]], [[kidney]], [[brain]] and [[bone marrow]].<ref name="www.ncbi.nlm.nih.gov">{{Cite web | last = | first = |title = Recurrence of thymoma: clinicopathological feat... [J Surg Oncol. 2001] - PubMed - NCBI | url = http://www.ncbi.nlm.nih.gov/pubmed/11745803 | publisher = | date = | accessdate = }}</ref> | *The most common sites of distant recurrence are [[lung]], [[liver]], [[bone]], [[kidney]], [[brain]], and [[bone marrow]].<ref name="www.ncbi.nlm.nih.gov">{{Cite web | last = | first = |title = Recurrence of thymoma: clinicopathological feat... [J Surg Oncol. 2001] - PubMed - NCBI | url = http://www.ncbi.nlm.nih.gov/pubmed/11745803 | publisher = | date = | accessdate = }}</ref> | ||
==Complications== | ==Complications== | ||
| Line 17: | Line 17: | ||
*The most important factor for prognosis is the stage and grade of the thymic carcinoma. | *The most important factor for prognosis is the stage and grade of the thymic carcinoma. | ||
*The 5-year and 10-year overall survival rates in patients with thymic carcinoma are 38% and 28% | *The 5-year and 10-year overall survival rates in patients with thymic carcinoma are 38% and 28% respectively.<ref name="Ogawa-2002">{{Cite journal | last1 = Ogawa | first1 = K. | last2 = Toita | first2 = T. | last3 = Uno | first3 = T. | last4 = Fuwa | first4 = N. | last5 = Kakinohana | first5 = Y. | last6 = Kamata | first6 = M. | last7 = Koja | first7 = K. | last8 = Kinjo | first8 = T. | last9 = Adachi | first9 = G. | title = Treatment and prognosis of thymic carcinoma: a retrospective analysis of 40 cases. | journal = Cancer | volume = 94 | issue = 12 | pages = 3115-9 | month = Jun | year = 2002 | doi = 10.1002/cncr.10588 | PMID = 12115342 }}</ref> | ||
*The subtypes squamous cell carcinoma, mucoepidermoid and basaloid carcinoma have a better prognosis than other histological subtypes | *The subtypes squamous cell carcinoma, mucoepidermoid, and basaloid carcinoma have a better prognosis than other histological subtypes. | ||
==References== | ==References== | ||
Latest revision as of 16:47, 29 December 2019
|
Thymic Carcinoma Microchapters |
|
Diagnosis |
|---|
|
Case Studies |
|
Thymic carcinoma natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Thymic carcinoma natural history, complications and prognosis |
|
FDA on Thymic carcinoma natural history, complications and prognosis |
|
CDC on Thymic carcinoma natural history, complications and prognosis |
|
Thymic carcinoma natural history, complications and prognosis in the news |
|
Blogs on Thymic carcinoma natural history, complications and prognosis |
|
Risk calculators and risk factors for Thymic carcinoma natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Marjan Khan M.B.B.S.[2]
Overview
Thymic carcinomas are generally considered indolent tumors due to long recurrence intervals (median of 68 months). The most common sites of distant recurrence are lung, liver, bone, kidney, brain, and bone marrow.[1] The most important factor for prognosis is the stage and grade of the thymic carcinoma. The 5-year and 10-year overall survival rates in patients with thymic carcinoma are 38% and 28%, respectively.[2] The subtypes squamous cell carcinoma, mucoepidermoid carcinoma, and basaloid carcinoma have a better prognosis than other histological subtypes. There are no reported cases of complications regarding the carcinoma by itself. Most complications occur during surgery and biopsy. The most important factor for prognosis is the stage and grade of the thymic carcinoma. The 5-year and 10-year overall survival rates in patients with thymic carcinoma are 38% and 28% respectively. Thymic malignancies are among the most common mediastinal primary tumors with up to 50% of anterior mediastinal masses proving to be of thymic descent. Invasive thymomas and thymic carcinomas are relatively rare tumors, which together represent about 0.2% to 1.5% of all malignancies.
Natural History
- Thymic carcinomas are generally considered indolent tumors due to long recurrence intervals (median of 68 months).
- Overall, for patients diagnosed with a resectable thymic tumor, 16% of them will recur after radical resection, either through local pleural or ganglionar recurrence or through distant metastatic spread.
- The most common sites of distant recurrence are lung, liver, bone, kidney, brain, and bone marrow.[1]
Complications
- There are no reported cases of complications regarding the carcinoma by itself.
- Most complications occur during surgery and biopsy.
Prognosis
- The most important factor for prognosis is the stage and grade of the thymic carcinoma.
- The 5-year and 10-year overall survival rates in patients with thymic carcinoma are 38% and 28% respectively.[2]
- The subtypes squamous cell carcinoma, mucoepidermoid, and basaloid carcinoma have a better prognosis than other histological subtypes.
References
- ↑ 1.0 1.1 "Recurrence of thymoma: clinicopathological feat... [J Surg Oncol. 2001] - PubMed - NCBI".
- ↑ 2.0 2.1 Ogawa, K.; Toita, T.; Uno, T.; Fuwa, N.; Kakinohana, Y.; Kamata, M.; Koja, K.; Kinjo, T.; Adachi, G. (2002). "Treatment and prognosis of thymic carcinoma: a retrospective analysis of 40 cases". Cancer. 94 (12): 3115–9. doi:10.1002/cncr.10588. PMID 12115342. Unknown parameter
|month=ignored (help)